SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp

Shire plc

Miesian Plaza
Blocks 2 and 3 50-58 Baggot Street Lower
Dublin 2
Ireland
353 1 609 6000
http://www.shire.com

SectorHealthcare
IndustryBiotechnology
Full-time employees23,044

Key executives

NameTitlePayExercisedYear born
Dr. Flemming Ornskov M.P.H., MBA, M.D., MPHCEO, MD & Exec. Director5.43MN/A1958
Mr. Thomas J. W. DittrichCFO & DirectorN/AN/A1964
Gisele DionChief Accounting OfficerN/AN/AN/A
Mr. Matthew WalkerHead of Technical OperationsN/AN/A1964
Prof. Andreas Busch Ph.D.Head of R&D & Chief Scientific OfficerN/AN/A1963
Amounts are as of 31 December 2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Corporate governance

Shire plc’s ISS governance QualityScore as of 1 May 2018 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes